Literature DB >> 32013843

The Medical Device Applied to Uterine Fibroids Morcellation: Analysis of Critical Biological Issues and Drawbacks from A Medical-Legal Prospective.

Ospan A Mynbaev1, Radmila Sparic2, Michael Stark3, Antonio Malvasi4, Enrico Marinelli5, Simona Zaami5, Andrea Tinelli6.   

Abstract

Following the FDA safety communication of 2014 increasing attention has been to the treatment of uterine fibroids, due to the suspicion of a potential leiomyosarcoma (ULM). FDA banned the use of power morcellation in the US, since this technique is likely to spread malignant cells from an unsuspected ULM. We criticized the medical legal consequences of this banning among gynecologists and patients, focusing on the drawbacks of biology and surgery. The authors analyzed literature data on one side, on the incidence, diagnosis and treatment of leiomyoma and ULM, and the other side, on the power morcellations and related critical issues, trying to highlight their main controversial aspects and to outline the possible impact on patients and on medical responsibility. The alternative methods to power morcellation are more invasive surgical solutions (as mini laparotomy or culdotomy), which inevitably involve associated risks with the surgical procedure as such and always request the containing bags. Although the in-bag morcellation is a promising technique, currently the used devices are largely off-label. This highlights the surgical risk, in case of complications, of suffering for malpractice claims both for not having used a containment system, favoring the spread of the neoplasm, and for its off-label use. Since the diagnosis of ULM is by histology after surgery, the fear of legal consequences or medical malpractice for unknown ULM power morcellation, should be targeted to analyze, in terms of cost/benefit ratio, the surgical priority. It should focus on the prevention of the risk of having a rare and statistically limited ULM or on the surgical-related complications, often linked to a slowdown minimally invasive surgery, or on the use of the authorized in-bag morcellations. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Uterine fibroid; in bag morcellation; laparoscopic myomectomy; leiomyosarcoma; medical liability; power morcellation.

Mesh:

Year:  2020        PMID: 32013843     DOI: 10.2174/1381612826666200204093737

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Surgical Treatment of "Large Uterine Masses" in Pregnancy: A Single-Center Experience.

Authors:  Anna Franca Cavaliere; Annalisa Vidiri; Salvatore Gueli Alletti; Anna Fagotti; Maria Concetta La Milia; Silvia Perossini; Stefano Restaino; Giuseppe Vizzielli; Antonio Lanzone; Giovanni Scambia
Journal:  Int J Environ Res Public Health       Date:  2021-11-19       Impact factor: 3.390

2.  Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports.

Authors:  Antonio Macciò; Elisabetta Sanna; Fabrizio Lavra; Piergiorgio Calò; Clelia Madeddu
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.